XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Research and development expenses $ 2,063 $ 1,693 $ 7,800 $ 2,962
Marketing expenses 125 295
General and administrative expenses 1,063 531 2,598 1,725
Total operating expenses 3,251 2,224 10,693 4,687
Operating loss 3,251 2,224 10,693 4,687
Other income (12) (12)
Finance (income) expenses, net (Note 5) 1,848 (1) 1,822 (2)
Net Loss 5,087 2,223 12,503 4,685
Other comprehensive (income) loss:        
Foreign currency translation adjustment 17 (6) 11 (17)
Comprehensive loss for the period $ 5,104 $ 2,217 $ 12,514 $ 4,668
Basic net loss per common stock $ (0.91) $ (0.49) $ (2.39) $ (1.38)
Diluted net loss per common stock $ (0.91) $ (0.49) $ (2.39) $ (1.38)
Weighted average number of common stock outstanding used in computing basic net loss per share 5,594,880 4,593,733 5,355,806 4,006,527
Weighted average number of common stock outstanding used in computing diluted net loss per share 5,594,880 4,593,733 5,355,806 4,006,527